A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel

Contraception

Volumn 72, Issue 2, 2005, Pages 98-104

  Jespersen, Jørgen ^a,b   Endrikat, Jan ^c   Düsterberg, Bernd ^c   Schmidt, Werner ^d   Gerlinger, Christoph ^c   Wessel, Jens ^c   Sidelmann, Johannes J ^a,b   Skouby, Sven O ^e  

^a ESBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c BAYER PHARMA AG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dose reduction; Ethinylestradiol; Hemostasis; Levonorgestrel; Oral contraceptives

Indexed keywords

ANTIGEN; D DIMER; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FIBRIN DEGRADATION PRODUCT; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG;

ACNE; ADULT; ANTICOAGULATION; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; EVALUATION; FEMALE; FIBRINOLYSIS; HEADACHE; HEMOSTASIS; HUMAN; MASTALGIA; MEASUREMENT; NAUSEA; NORMAL HUMAN; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; CONTRACEPTION; CONTRACEPTIVES, ORAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HEMOSTASIS; HUMANS; LEVONORGESTREL; PROSPECTIVE STUDIES;

EID: 22044452540     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2005.01.006     Document Type: Article

References (32)

1. B. Dusterberg, H. Ellman, U. Muller, E. Rowe, and B. Muhe A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene Gynecol Endocrinol 10 1996 33 39
2. J. Nevinny-Stickel German trial of an oral contraceptive containing 0.150 mg desogestrel plus 0.020 mg ethinylestradiol Acta Obstet Gynecol Scand 44 1988 19 21
3. J.R. Newton, C. D'arcangues, and P.E. Hall A review of "once-a-month" combined injectable contraceptives J Obstet Gynaecol 4 Suppl 1 1994 S1 S34
4. A. Teichmann, A. Corbin, and Levonorgestrel Clinical experience with a monophasic oral contraceptive containing 150 μg levonorgestrel and 30 μg ethinylestradiol: efficacy, tolerance and metabolic interactions 1998 Thieme Stuttgart 81 91
5. R. Bannemerschult, J.P. Hanker, C. Wunsch, P. Fox, M. Albring, and K. Brill A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles Contraception 56 1997 285 290
6. J. Endrikat, B. Dusterberg, A. Ruebig, C. Gerlinger, and T. Strowitzki Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study Contraception 60 1999 269 274
7. R.C. Hite, R. Bannemerschult, P. Fox-Kuchenbecker, R. Turck, and K. Brill Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany Eur J Contracept Reprod Health Care 4 1999 7 13
8. D. Crook, and I. Godsland Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism Contraception 57 1998 189 201
9. C. Kluft, M.P. de Maat, L.A. Heinemann, M. Spannagl, and W. Schramm Importance of levonorgestrel dose in oral contraceptives for effects on coagulation Lancet 354 1999 832 833
10. U.H. Winkler, A.E. Schindler, J. Endrikat, and B. Dusterberg A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol Contraception 53 1996 75 84
11. S.O. Skouby, J. Endrikat, and B. Düsterberg A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel Contraception 71 2005 111 117
12. J. Endrikat, C. Klipping, and M. Cronin An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables Contraception 65 2002 215 221
13. E.M. Bladbjerg, P. Marckmann, B. Sandstrom, and J. Jespersen Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet Thromb Haemost 71 1994 755 758
14. J. Gram, and J. Jespersen Improved assay of antithrombin-III. Effects of certain additives on thrombin and on chromogenic peptide substrates Clin Chem 31 1985 1683 1688
15. M. Kraus, M. Noah, and K. Fickenscher The PCAT - a simple screening assay for assessing the functionality of the protein C anticoagulant pathway Thromb Res 79 1995 217 222
16. J. Gram, and J. Jespersen A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples Thromb Haemost 53 1985 255 259
17. M. Ranby, N. Bergsdorf, T. Nilsson, G. Mellbring, B. Winblad, and G. Bucht Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay Clin Chem 32 1986 2160 2165
18. P.J. Declerck, H. Moreau, J. Jespersen, J. Gram, and C. Kluft Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1) Thromb Haemost 70 1993 858 863
19. J. Gram, and J. Jespersen A simplified estimation of tissue plasminogen activator (t-PA) inhibition in human plasma Fibrinolysis 1 1987 33 37
20. J. Gram, P.J. Declerck, J. Sidelmann, J. Jespersen, and C. Kluft Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity Thromb Haemost 70 1993 852 857
21. Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease. The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995. Writing committee Gynecol Endocrinol 10 1996 1 5
22. C. Kluft, and M. Lansink Effect of oral contraceptives on haemostasis variables Thromb Haemost 78 1997 315 326
23. U.H. Winkler, T. Holscher, H. Schulte, J.P. Zierleyn, W. Collet, and A.E. Schindler Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system Gynecol Endocrinol 10 1996 265 271
24. U.H. Winkler, E. Daume, and R. Sudik A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel Eur J Contracept Reprod Health Care 4 1999 145 154
25. U.H. Winkler Blood coagulation and oral contraceptives. A critical review Contraception 57 1998 203 209
26. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. Outline of the protocol. Oral contraceptive and hemostasis study group Contraception 59 1999 345 355
27. Oral Contraceptive and Hemostasis Study Group The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study Contraceptive 67 2003 173 185
28. J.C. Meijers, S. Middeldorp, and W. Tekelenburg Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives Thromb Haemost 84 2000 9 14
29. S. Middeldorp, J.C. Meijers, and A.E. van den Ende Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study Thromb Haemost 84 2000 4 8
30. R.N. Prasad, S.C. Koh, O.A. Viegas, and S.S. Ratnam Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel Clin Appl Thromb Hemost 5 1999 60 70
31. B.B. Gertsman, J.M. Piper, D.K. Tomita, W.J. Ferguson, B.V. Stadel, and F.E. Lundin Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease Am J Epidemiol 133 1991 32 37
32. O. Lidegaard Oral contraceptives and venous thromboembolism: an epidemiological review Eur J Contracept Reprod Health Care 1 1996 13 20